Find trials
Search tips

A Study Of Vector Flow Mapping (VFM) In Myectomy, Ablation, And Mavacamten Therapy

Overview

About this study

The purpose of this study is to assess the feasibility of VFM to detect acute changes in Left Ventricular Energy Loss (LV-EL) and Wall Shear Stress (WSS) in patients undergoing three distinct therapeutic interventions for obstructive HCM.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Diagnosis of Hypertrophic Cardiomyopathy (septal thickness ≥15 mm).

  • Resting or provoked LVOT gradient ≥ 15 mmHg.

  • Scheduled for one of the three defined interventions (Mavacamten initiation, Myectomy, ASA).

  • Age ≥ 18 years.

Exclusion Criteria:

  • Poor acoustic windows precluding valid VFM analysis.

  • Significant arrhythmias (e.g., persistent Atrial Fibrillation) preventing reliable 3-beat averaging.

  • Concomitant severe valve disease (unrelated to HCM) requiring separate intervention.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 01/26/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Sunil Mankad, M.D.

Contact us for the latest status

Contact information:

Fadi Adel

(507) 284-3681

adel.fadi@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20605690

Mayo Clinic Footer